Axsome Therapeutics (AXSM) Intangibles (2022 - 2026)

Axsome Therapeutics has disclosed Intangibles across 5 years of filings, most recently posting $38.9 million for Q1 2026.

• Intangibles for Q1 2026 came in at $38.9 million, down 38.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.9 million (down 38.95% YoY), and the FY2025 annual result was $63.8 million, up 36.05% from the prior year.
• Intangibles came in at $38.9 million for Q1 2026 at Axsome Therapeutics, down from $63.8 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $63.8 million in Q2 2022 to a low of $38.9 million in Q1 2026.
• The 5-year median for Intangibles is $61.7 million (2022), against an average of $57.9 million.
• Across the five-year window, Intangibles jumped 36.05% in 2025 and sank 38.95% in 2026, its largest moves.
• Axsome Therapeutics' Intangibles stood at $59.7 million in 2022, then decreased by 10.69% to $53.3 million in 2023, then declined by 12.0% to $46.9 million in 2024, then soared by 36.05% to $63.8 million in 2025, then tumbled by 38.95% to $38.9 million in 2026.
• The last three Intangibles figures came in at $38.9 million (Q1 2026), $63.8 million (Q4 2025), and $63.8 million (Q3 2025), per Business Quant data.